Today's Date: June 25, 2022
Global Surrogacy Services Announces Outreach to Potential Gestational Surrogates in Three Southwestern States   •   PEOPLE's Food Awards 2022 Winner – LaCroix Cherry Blossom: "It’s Like Spring in a Can!”   •   Fred Hahn and CUPE Ontario at the Toronto Pride Parade   •   Construction Has Started at Vaughan’s Sold Out Vincent Condominiums   •    Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for Women of Color   •   NCCI Golf Event Generates $25,000 for Kids' Chance of America Scholarships   •   Avita Adds Two New Members to Board of Directors   •   First Command Reports: Financial Optimism Remains Strong in Career Military Families   •   MUJEN® Kicks off the Summer in NYC With Andy Cohen’s Pride Party and the 70’s Themed DiscOasis in Central Par   •   Four recipients of the 2022 Awards of Excellence in Nursing announced from Indigenous Services Canada   •   Five Bluum Standouts Honored on CRN 2022 Women of the Channel List   •   Closing the Health Disparity Gap for Black Women   •   RNR Tire Express Surprises Tampa-Area Woman with New Car in Mother's Day Giveaway   •   Equitable Bank Releases Inaugural ESG Performance Report   •   Tracey Hayes from MicroAge Named on CRN's 2022 Women of the Channel Power 70 Solution Providers List   •   Denver Health Names Donna Lynne Next CEO   •   Flow Beverage Corp. Announces Official Sponsorship with Pride Toronto   •   Mrs. Flowers Takes the Helm at Comfort Home Care, Rockville, MD   •   Checkmarx' Ana Lucia Amaral Honored as a CRN 2022 Woman of the Channel   •   Marsha P. Johnson Institute: Supreme Court Ruling on Roe V. Wade Is an Unjust Attack on Human Rights
Bookmark and Share

UN Study: It’s Time To Reassess Where We Stand With An HIV Vaccine

 

 

 

 

According to a recent United Nations study, HIV infection rates among high-risk groups such as gays, drug users and sex workers are on the rise around the world.

U.N. AIDS agency chief Michel Sidibe is saying the increase may be due to worsening discrimination against these groups in certain countries. In the U.S., despite laws that are more tolerant of homosexuality, more than half of all new HIV infections in 2009 occurred among gay men, which Sidibe called "shocking." In the U.S., Sidibe said, "it seems like we have come full circle," and not in a good way.

Contrary to what many perceive, HIV is not going away. These increases in HIV rates nationally and globally demand a renewed focus on how the international community can battle this pandemic.

Mark J. Newman, Ph.D., Vice President of Research and Development at GeoVax Labs, Inc., a biotechnology company focusing on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV), believes now is a better time than ever to begin reassessing the importance not only of a preventative vaccine to address the high-risk population, but also of a therapeutic vaccine to keep those with active HIV from progressing to full-blown AIDS.

Dr. Newman is available to discuss: 
Can vaccines curb the rising numbers of HIV cases? 
What are the challenges of bringing a vaccine for HIV to market? 
What has stalled progress and what does the future hold? 
How is science harnessing the power of the immune system to fight HIV?

About Dr. Mark J. Newman 
In a career spanning 30 years, Dr. Newman, was Vice President, Research and Development for PaxVax, Inc., prior to joining GeoVax. At PaxVax, he led research and preclinical development of Adenovirus vectored vaccine candidates. During his professional life he has worked on the development of HIV, influenza and cancer vaccines and led active programs on adjuvant and vaccine delivery technologies. Over the past 20 years he has served in various senior management roles within the biotechnology field with a focus on HIV/AIDS vaccines. He holds B.Sc. and M.Sc. degrees from Ohio State University. He also holds a Ph.D. in Immunology from the John Curtin School of Medical Research at the Australian National University. In his scientific career he has successfully secured peer-reviewed grants and contracts, is an inventor on seven issued patents, and an author of more than 100 peer-reviewed scientific papers. He has provided extensive service to the field of HIV/AIDS vaccines by serving on extramural panels for the review of US NIH-sponsored HIV/AIDS and vaccine research programs.

About GeoVax Labs, Inc. 
The ongoing research and development programs at GeoVax are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent development of AIDS in healthy individuals who are exposed to the HIV virus and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus.

For further information about GeoVax Labs, Inc. please visit:www.geovax.com

 
Source: GeoVax Labs



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News